Re: Gianluca Giannarini, Thomas M. Kessler, Fr?d?ric D. Birkh?user, George N. Thalmann, Urs E. Studer. Antegrade perfusion with bacillus calmette-gu?rin in patients with non-muscle-invasive urothelial carcinoma of the upper urinary tract: Who may benefit? Eur Urol 2011;60:955-60

Chung S.-D.SHIH-CHIEH CHUEHCHAO-YUAN HUANGHONG-JENG YU2021-02-022021-02-0220120302-2838https://www.scopus.com/inward/record.uri?eid=2-s2.0-84856365873&doi=10.1016%2fj.eururo.2011.12.004&partnerID=40&md5=f953921df7a94f97500d05e4fade2725https://scholars.lib.ntu.edu.tw/handle/123456789/544146[SDGs]SDG3BCG vaccine; cancer adjuvant therapy; cancer control; consensus; drug efficacy; follow up; histopathology; human; letter; patient positioning; perfusion; priority journal; retrospective study; transitional cell carcinoma; treatment outcome; treatment response; ureter obstruction; urinary tract carcinoma; Antineoplastic Agents; BCG Vaccine; Carcinoma; Humans; Urologic NeoplasmsRe: Gianluca Giannarini, Thomas M. Kessler, Fr?d?ric D. Birkh?user, George N. Thalmann, Urs E. Studer. Antegrade perfusion with bacillus calmette-gu?rin in patients with non-muscle-invasive urothelial carcinoma of the upper urinary tract: Who may benefit? Eur Urol 2011;60:955-60letter10.1016/j.eururo.2011.12.004221974402-s2.0-84856365873